128 related articles for article (PubMed ID: 29172294)
1. Association of Voltage-Gated Sodium Channel Genetic Polymorphisms with Oxaliplatin-Induced Chronic Peripheral Neuropathy in South Indian Cancer Patients.
Palugulla S; Thakkar DN; Kayal S; Narayan SK; Dkhar SA
Asian Pac J Cancer Prev; 2017 Nov; 18(11):3157-3165. PubMed ID: 29172294
[TBL] [Abstract][Full Text] [Related]
2. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
Argyriou AA; Cavaletti G; Antonacopoulou A; Genazzani AA; Briani C; Bruna J; Terrazzino S; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Psaromyalou A; Angelopoulou A; Kalofonos HP
Cancer; 2013 Oct; 119(19):3570-7. PubMed ID: 23821303
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients.
Palugulla S; Devaraju P; Kayal S; Narayan SK; Mathaiyan J
Cancer Chemother Pharmacol; 2018 Sep; 82(3):421-428. PubMed ID: 29936608
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy.
Sereno M; Gutiérrez-Gutiérrez G; Rubio JM; Apellániz-Ruiz M; Sánchez-Barroso L; Casado E; Falagan S; López-Gómez M; Merino M; Gómez-Raposo C; Rodriguez-Salas N; Tébar FZ; Rodríguez-Antona C
BMC Cancer; 2017 Jan; 17(1):63. PubMed ID: 28103821
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin-induced Peripheral Neuropathy in South Indian Cancer Patients: A Prospective Study in Digestive Tract Cancer Patients.
Palugulla S; Dkhar SA; Kayal S; Narayan SK
Indian J Med Paediatr Oncol; 2017; 38(4):502-507. PubMed ID: 29333020
[TBL] [Abstract][Full Text] [Related]
6. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.
Terrazzino S; Argyriou AA; Cargnin S; Antonacopoulou AG; Briani C; Bruna J; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP; Canonico PL; Genazzani AA; Cavaletti G
J Peripher Nerv Syst; 2015 Mar; 20(1):15-23. PubMed ID: 25858589
[TBL] [Abstract][Full Text] [Related]
7. Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Antonacopoulou AG; Alberti P; Briani C; Bruna J; Velasco R; Anastopoulou GG; Park SB; Cavaletti G; Kalofonos HP
J Peripher Nerv Syst; 2019 Dec; 24(4):298-303. PubMed ID: 31486252
[TBL] [Abstract][Full Text] [Related]
8. Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Psimaras D; Bruna J; Kalofonos HP
J Peripher Nerv Syst; 2020 Jun; 25(2):178-183. PubMed ID: 32277545
[TBL] [Abstract][Full Text] [Related]
9. Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer.
Hsu SY; Huang WS; Lee SH; Chu TP; Lin YC; Lu CH; Beaton RD; Jane SW
Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12976. PubMed ID: 30536809
[TBL] [Abstract][Full Text] [Related]
10. Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study.
Argyriou AA; Briani C; Cavaletti G; Bruna J; Alberti P; Velasco R; Lonardi S; Cortinovis D; Cazzaniga M; Campagnolo M; Santos C; Kalofonos HP
Eur J Neurol; 2013 May; 20(5):788-94. PubMed ID: 23252594
[TBL] [Abstract][Full Text] [Related]
11. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
Briani C; Argyriou AA; Izquierdo C; Velasco R; Campagnolo M; Alberti P; Frigeni B; Cacciavillani M; Bergamo F; Cortinovis D; Cazzaniga M; Bruna J; Cavaletti G; Kalofonos HP
J Peripher Nerv Syst; 2014 Dec; 19(4):299-306. PubMed ID: 25582667
[TBL] [Abstract][Full Text] [Related]
12. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
Velasco R; Bruna J; Briani C; Argyriou AA; Cavaletti G; Alberti P; Frigeni B; Cacciavillani M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP
J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):392-8. PubMed ID: 23813745
[TBL] [Abstract][Full Text] [Related]
13. Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN).
Argyriou AA
Toxics; 2015 May; 3(2):187-197. PubMed ID: 29056657
[TBL] [Abstract][Full Text] [Related]
14. The Incidence of Oxaliplatin-Induced Peripheral Neurotoxicity at Khartoum Oncology Hospital: A Cross-Sectional Survey.
Ali NT; Mohamed AA; Yousef BA
Asia Pac J Oncol Nurs; 2020; 7(3):266-272. PubMed ID: 32642498
[TBL] [Abstract][Full Text] [Related]
15. Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity.
Velasco R; Alemany M; Villagrán M; Argyriou AA
J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357136
[TBL] [Abstract][Full Text] [Related]
16. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients.
Won HH; Lee J; Park JO; Park YS; Lim HY; Kang WK; Kim JW; Lee SY; Park SH
Cancer; 2012 Jun; 118(11):2828-36. PubMed ID: 22020760
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers.
Xu XT; Dai ZH; Xu Q; Qiao YQ; Gu Y; Nie F; Zhu MM; Tong JL; Ran ZH
J Dig Dis; 2013 Jun; 14(6):288-98. PubMed ID: 23432969
[TBL] [Abstract][Full Text] [Related]
18. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy.
Kautio AL; Haanpää M; Kautiainen H; Leminen A; Kalso E; Saarto T
Anticancer Res; 2011 Oct; 31(10):3493-6. PubMed ID: 21965767
[TBL] [Abstract][Full Text] [Related]
20. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy.
Argyriou AA; Antonacopoulou AG; Scopa CD; Kottorou A; Kominea A; Peroukides S; Kalofonos HP
Oncology; 2009; 77(3-4):254-6. PubMed ID: 19738391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
